Currently, two tyrosine kinase inhibitors—osimertinib in EGFR mutant and alectinib in ALK-rearranged NSCLC—have been approved by the FDA for treatment of this disease in the adjuvant setting. The gene discussed is ALK; the disease is non-small cell lung carcinoma.